CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
K Pan, H Farrukh, VCSR Chittepu, H Xu, C Pan… - Journal of Experimental …, 2022 - Springer
Adoptive cell therapy with chimeric antigen receptor (CAR) immunotherapy has made
tremendous progress with five CAR T therapies approved by the US Food and Drug …
tremendous progress with five CAR T therapies approved by the US Food and Drug …
The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies
A Daei Sorkhabi, L Mohamed Khosroshahi… - Frontiers in …, 2023 - frontiersin.org
The successful outcomes of chimeric antigen receptor (CAR) T-cell therapy in treating
hematologic cancers have increased the previously unprecedented excitement to use this …
hematologic cancers have increased the previously unprecedented excitement to use this …
Tumor immune microenvironment in head and neck cancers
SMY Chen, AL Krinsky, RA Woolaver… - Molecular …, 2020 - Wiley Online Library
Head and neck cancers are a heterogeneous group of tumors that are highly aggressive
and collectively represent the sixth most common cancer worldwide. Ninety percent of head …
and collectively represent the sixth most common cancer worldwide. Ninety percent of head …
Bispecific T-cell redirection versus chimeric antigen receptor (CAR)-T cells as approaches to kill cancer cells
WR Strohl, M Naso - Antibodies, 2019 - mdpi.com
The concepts for T-cell redirecting bispecific antibodies (TRBAs) and chimeric antigen
receptor (CAR)-T cells are both at least 30 years old but both platforms are just now coming …
receptor (CAR)-T cells are both at least 30 years old but both platforms are just now coming …
Role of miRNAs in immune responses and immunotherapy in cancer
In the past decade, the study of mechanisms of cancer immunity has seen a prominent
boom, which paralleled the increased amount of research on the clinical efficacy of immune …
boom, which paralleled the increased amount of research on the clinical efficacy of immune …
Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment
Background Pancreatic cancer is one of the most lethal type of cancers, with an overall five-
year survival rate of less than 5%. It is usually diagnosed at an advanced stage with limited …
year survival rate of less than 5%. It is usually diagnosed at an advanced stage with limited …
Chimeric antigen receptor-modified T cell therapy in multiple myeloma: beyond B cell maturation antigen
M Timmers, G Roex, Y Wang… - Frontiers in …, 2019 - frontiersin.org
Chimeric antigen receptor (CAR)-modified T cell therapy is a rapidly emerging
immunotherapeutic approach that is revolutionizing cancer treatment. The impressive …
immunotherapeutic approach that is revolutionizing cancer treatment. The impressive …
MLL-Rearranged Acute Leukemia with t(4;11)(q21;q23)—Current Treatment Options. Is There a Role for CAR-T Cell Therapy?
The MLL (mixed-lineage leukemia) gene, located on chromosome 11q23, is involved in
chromosomal translocations in a subtype of acute leukemia, which represents approximately …
chromosomal translocations in a subtype of acute leukemia, which represents approximately …
Monitoring CAR T‐cells using flow cytometry
J Demaret, P Varlet, J Trauet… - Cytometry Part B …, 2021 - Wiley Online Library
Background Chimeric antigen receptor (CAR) T‐cell therapy is considered as a major
scientific breakthrough in cancer immunotherapy. The success of adoptive CAR T‐cell …
scientific breakthrough in cancer immunotherapy. The success of adoptive CAR T‐cell …
[HTML][HTML] Role of immunotherapy in Ewing sarcoma
Ewing sarcoma (ES) is thought to arise from mesenchymal stem cells and is the second
most common bone sarcoma in pediatric patients and young adults. Given the dismal overall …
most common bone sarcoma in pediatric patients and young adults. Given the dismal overall …